Inquis Medical Secures $40 Million in Series B Funding

Inquis Medical is $40 million more solvent, having closed an oversubscribed Series B financing round led by Marshall Wace.

“We are thrilled to have successfully secured our Series B funding. This is a strong validation of the confidence investors have in our mission and the potential impact of our innovations,” Inquis Medical Co-CEO/Co-Founder Vahid Saadat said.

Besides Marshall Wace, the company also received financial support from ShangBay Capital, Yu Star, EnPointe Ventures, and Pierre Lamond. The money positions Inquis Medical for significant growth and development as it advances its technologies and prepares for commercialization.

Inquis Medical’s flagship product, the Aventus Precision Thrombectomy System, features proprietary tissue-sensing technology that provides operators with real-time information on the tissue composition in contact with the device. This system offers enhanced precision and control during procedures, pushing the boundaries of possibilities achievable by current thrombectomy systems.

Inquis received U.S. Food and Drug Administration (FDA) 510(k) clearance earlier this year for its Aventus Thrombectomy System as well as its blood return system for peripheral indications, and has nearly completed enrollment in an FDA Investigational Device Exemption (IDE) pivotal clinical study targeting pulmonary embolism (PE) patients.

“This substantial investment from Marshall Wace, along with our existing investors, underscores a strong belief in both our technology and our team,” Inquis Medical Co-CEO/Co-Founder Mojgan Saadat stated. “We are excited for the next phase of the company and look forward to enhancing patient care by empowering physicians with our unique technology.”

In connection with the Series B financing, Andrew D. Goldberg, M.D., a portfolio manager at Marshall Wace, has joined Inquis Medical’s Board of Directors.

This $40 million in financing will enable the company to complete its pivotal IDE trial, prepare for the commercial launch of the Aventus Thrombectomy System in 2025, and continue to advance its proprietary tissue-sensing platform.

Up to 900,000 U.S. residents are affected by venous thromboembolism (VTE) annually, with more than 50% of deep vein thrombosis cases leading to PE—the third leading cause of cardiovascular death. Current lytic-free aspiration thrombectomy procedures are often limited by significant blood loss and procedural inefficiencies, making Inquis Medical’s innovations a promising advancement in the field.

Inquis Medical is a clinical-stage medical device company focused on peripheral vascular innovations. The company is developing next-generation thrombectomy technology that offers physicians improved control and precision, enhances procedural efficiency, and minimizes blood loss. Founded in 2020, Inquis Medical is led by a seasoned executive team with more than three decades of combined experience in developing, launching, and supporting novel medical devices that address unmet clinical needs and deliver lasting impact.